BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
53.49
+0.82 (1.56%)
NASDAQ · Last Trade: Oct 28th, 6:14 PM EDT
Detailed Quote
Previous Close
52.67
Open
53.40
Bid
53.49
Ask
55.70
Day's Range
53.27 - 56.80
52 Week Range
51.56 - 73.51
Volume
6,452,951
Market Cap
9.81B
PE Ratio (TTM)
15.83
EPS (TTM)
3.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,328,665
Chart
About BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
Biomarin Pharmaceuticals is a biotechnology company that specializes in developing and commercializing innovative therapies for rare genetic disorders and critical diseases. The company focuses on creating treatments for patients with serious and life-threatening conditions, often targeting specific genetic mutations. Biomarin’s research and product development emphasize precision medicine, with a commitment to advancing therapeutic options and improving the quality of life for individuals affected by these rare diseases. Through its work, Biomarin strives to address unmet medical needs and enhance patient care through scientific innovation. Read More
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN)
jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a slight increase in its full-year revenue forecast.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.18 billion at the midpoint. Its non-GAAP profit of $0.12 per share was 62.5% below analysts’ consensus estimates.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.18 billion at the midpoint. Its non-GAAP profit of $0.12 per share was 62.5% below analysts’ consensus estimates.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN)
will be announcing earnings results this Monday after market close. Here’s what you need to know.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 13.6% gain for healthcare stocks has fallen short of the S&P 500’s 25.5% rise.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
BioMarin is a strong value stock with a low P/E ratio, robust financial health, and solid profitability, offering a compelling safety margin for investors.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical (NASDAQ:BMRN) and the rest of the therapeutics stocks fared in Q2.
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN)
fell 2.8% in the morning session after HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and a $60 price target.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
